Repligen Corporation (RGEN)
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 166.89 -0.20%
RGEN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.62B
- P/E (TTM)
- 229.07
- Forward P/E
- 63.12
- EPS (TTM)
- $0.73
- Dividend yield
- None
- 52-week range
- 100.99 – 198.87
- Day range
- 165.99 – 175.04
- Volume / Avg
- 2.62M / 1.14M
- Beta
- —
- Shares outstanding
- 63.49M
- Next earnings
- Oct 27, 2026
52-week range
RGEN stock today
On Oct 7, RGEN ended the session at $167.22, shedding $7.64 (4.37%), versus the S&P 500's 0.22% decline. Volume was 2.3x the average at 2.62M shares, a sign of unusually heavy trading. At this level, RGEN sits in the middle of its 52-week range of $100.99 to $198.87: 15.9% below the high, set on Sep 28, 2026 and 65.6% above the low.
RGEN is up 2.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 14.6%. At 229.1x trailing earnings, Repligen trades above the peer-group median of 36.5x. Its forward P/E of 63.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 27; analysts expect EPS of $0.46.
Summary generated from market data by MetaCap's automated system. Methodology
About Repligen
Company profileRepligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Olivier Loeillot
- Headquarters
- Waltham, MA
- Employees
- 2,000
- IPO year
- 1986
- Website
- repligen.com
Financial highlights
Full financialsIn fiscal 2025, Repligen generated $738.3 million in revenue, up 16.4% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $48.9 million, for a net margin of 6.6% versus a median of 16.4% in the prior 5 years. Gross margin was 52.3% (up from 43.3%) and operating margin 7.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $738.26M | $634.44M | $632.36M | $801.54M | $670.53M |
| Growth | +16.36% | +0.33% | -21.11% | +19.54% | +83.08% |
| Net income | $48.89M | $-25.51M | $35.60M | $185.96M | $128.29M |
| EPS (diluted) | $0.86 | $-0.46 | $0.63 | $3.24 | $2.24 |
Analyst forecast
ForecastConsensus (22 analysts)
strong_buy
Avg. price target
$194.95+16.58%
- Strong buy 3
- Buy 15
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 27, 2026
- EPS estimate
- $0.46
- Last reported (Q2 2026)
- Jul 29, 2026
- EPS actual vs est.
- $0.09 vs —
RGEN news
All RGEN newsRepligen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IBRXImmunityBio Inc. | 9.75 | +0.62% | $10.33B | vs RGEN |
| TWSTTwist Bioscience Corporation | 155.65 | -6.78% | $10.32B | vs RGEN |
| PCVXVaxcyte Inc. | 66.96 | +0.39% | $9.96B | vs RGEN |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs RGEN |
| KRYSKrystal Biotech Inc. | 324.57 | -0.69% | $9.61B | vs RGEN |
| QGENQiagen N.V. | 44.79 | -1.88% | $9.25B | vs RGEN |
| KYMRKymera Therapeutics Inc. | 108.35 | +2.24% | $8.91B | vs RGEN |
| HALOHalozyme Therapeutics Inc. | 110.79 | +0.98% | $12.57B | vs RGEN |
Indexes, lists and sector
Repligen stock FAQ
What is Repligen's stock price today?
RGEN last traded at $167.22 as of Oct 7, 4:00 PM EDT, down 4.37% on the day. Prices are delayed at least 15 minutes.
When is Repligen's next earnings date?
Repligen is expected to report earnings on Tuesday, October 27, 2026. Analysts expect EPS of $0.46.
What is RGEN's P/E ratio?
RGEN trades at a trailing P/E ratio of 229.07 and a forward P/E of 63.12, compared with a median of 36.5 for its closest peers.
Who is Repligen's CEO?
Mr. Olivier Loeillot is the chief executive officer of Repligen Corporation, which has about 2,000 employees.
What is the RGEN 52-week high?
The 52-week high for RGEN is $198.87 and the 52-week low is $100.99. The stock is currently 15.9% below its high.